Nicolas Nesseler: Do We Overlook Factor XIII Deficiency in VA-ECMO Patients?
Nicolas Nesseler, Professor at University of Rennes, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Critical Care Journal, adding:
”Do we overlook Factor XIII deficiency in VA-ECMO patients?
We just published a prospective study in Critical Care – 50 patients on VA-ECMO, 413 FXIII measurements.
68percent spent most of their ECMO run with FXIII levels below 70percent. On average, 80percent of their support time in deficiency territory. And none of this is captured by routine PT or aPTT.
No clear trend over time. Huge variability between patients. No proven link with severe bleeding – but our sample size was limited.
The real question now: should we routinely monitor FXIII in these patients, and when does supplementation make sense?
Curious to hear from those managing ECMO patients daily.”
Title: Cumulative exposure to factor XIII deficiency during veno-arterial extracorporeal membrane oxygenation: a prospective cohort study
Authors: Nicolas Nesseler, Adeline Pontis, Erwan Flécher, Mathieu Beaudeau, Nicolas Patou-Parvedy, Isabelle Gouin-Thibault, Alexandre Mansour
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal